Inhaled Antibiotics Market Opportunities And Strategies 2024-2033 – Size, Growth Analysis, Outlook, Overview


Posted January 23, 2024 by harishtbrc

Global inhaled antibiotics market size is expected to reach $2.18 Bn by 2028 at a rate of 8.4%, segmented as by product type, aerosol or metered dose inhaler, dry powder formulation, spray, other types
 
The Inhaled Antibiotics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Inhaled Antibiotics Market:
https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report

According to The Business Research Company’s Inhaled Antibiotics Global Market Report 2024, The inhaled antibiotics market size has grown strongly in recent years. It will grow from $1.46 billion in 2023 to $1.58 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%.  The  growth in the historic period can be attributed to regulatory support and approvals, shift from systemic to targeted delivery, rise in antibiotic resistance, increase in respiratory infections..

The inhaled antibiotics market size is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%.  The growth in the forecast period can be attributed to growing investments in research and development, expansion of clinical applications, increasing focus on personalized medicine, advancements in drug formulations, continued antibiotic resistance concerns.. Major trends in the forecast period include continued innovation in formulations, patient-centric approach, increased research in respiratory health, shift towards targeted therapies, advancements in drug delivery systems..

The increasing incidence of respiratory diseases is expected to propel the growth of the inhaled antibiotics market going forward. Respiratory disease is a disease that damages the lungs and airways and impairs breathing in people. Inhaled antibiotics enhance lung function, prevent lung function decline, extend the period between exacerbations, and enhance the quality of life in cystic fibrosis patients. For instance, in June 2023, according to reports published by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths in 2021 i.e., 46,551 in Australia. Furthermore, in September 2022, according to the data published by The Lancet, a UK-based book and periodic data publishing organization, 11,255 new cases of respiratory syncytial virus (RSV) were recorded in the 2021 summer, which is 9.50% more. Therefore, an increasing incidence of respiratory diseases drives the inhaled antibiotics market .

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=7868&type=smp

The inhaled antibiotics market covered in this report is segmented –

1) By Product Type: Aerosol or Metered Dose Inhaler, Dry Powder Formulation, Spray, Other Types

2) By Application: Pneumonia, Asthma, Bronchitis, Other Applications

3) By End-User: Hospitals, Other End Users

Top Major Players:
Gilead Sciences Inc.
Lupin Limited
Insmed Inc.
Savara Inc.
Joincare Pharmaceutical Group Industry Co. Ltd

North America was the largest region in the inhaled antibiotics market share in 2023.

Investments in the development of inhaled antibiotics are a key trend gaining popularity in inhaled antibiotics market. Major pharmaceutical companies are investing in the development of inhaled antibiotics to sustain their position in the market. For instance, in December 2021, Enbiotix, a US-based drug development company invested $11 million in the development of antibiotics for lung infections. This funding would help with clinical testing of murepavadin, and ColiFin (inhaled colistimethate sodium) that are used for patients suffering from cystic fibrosis (CF).

The inhaled antibiotics market report table of contents includes:

1. Executive Summary
2. Inhaled Antibiotics Market Characteristics
3. Inhaled Antibiotics Market Trends And Strategies
4. Inhaled Antibiotics Market - Macro Economic Scenario
5. Global Inhaled Antibiotics Market Size and Growth
….….
31. Global Inhaled Antibiotics Market Competitive Benchmarking
32. Global Inhaled Antibiotics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Inhaled Antibiotics Market
34.Inhaled Antibiotics Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By TBRC
Country United States
Categories Technology
Tags inhaled antibiotics market share , inhaled antibiotics market size
Last Updated January 23, 2024